ADAMTS13 and COVID-19: In conclusion, the present study demonstrates for the first time, that a substantial part of patients with COVID-19 develop autoantibodies to ADAMTS13 in the course of their disease, occurring in approximately one third of hospitalized patients, which could not be seen in ICU patients without COVID-19.